Limerick, Ireland

Michaela Bowden

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michaela Bowden. Retrieved from https://idiyas.com/inventor/michaela-bowden-9tu0jrw1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michaela Bowden: Innovator in Cancer Treatment Biomarkers

Introduction

Michaela Bowden is a prominent inventor based in County Limerick, Ireland. She has made significant contributions to the field of cancer treatment through her innovative research and development of novel biomarkers. Her work focuses on improving the efficacy of treatment regimens for cancer patients.

Latest Patents

Michaela Bowden holds a patent titled "Biomarkers of tumor pharmacodynamic response." This invention provides novel biomarkers and methods for assessing the efficacy of treatment regimens for treating cancer, particularly through Hsp90 inhibition. The patent also outlines methods for identifying test agents capable of treating cancers characterized by high levels of IL-8. She has 1 patent to her name.

Career Highlights

Michaela is associated with Novartis AG, a leading global healthcare company. Her role at Novartis has allowed her to collaborate with other experts in the field and contribute to groundbreaking research in cancer treatment.

Collaborations

Michaela has worked alongside notable colleagues, including Alan J Buckler and Chantale T Guy. Their collaborative efforts have further advanced the research and development of effective cancer therapies.

Conclusion

Michaela Bowden's innovative work in cancer treatment biomarkers highlights her dedication to improving patient outcomes. Her contributions to the field are invaluable and continue to pave the way for future advancements in cancer therapy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…